Sunpharma

Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 croreCurrent reported value: INR 15,469 crore. No comparable prior figure is available in the source record. (+15.1Current 15.1 crore vs previous available quarter 8.6 crore.% YoY) and EBITDA of INR 4,949 croreCurrent reported value: INR 4,949 crore. No comparable prior figure is available in the source record. (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9%Current 31.9% vs previous available quarter 31.3%. on better product mix, while PAT grew 16%Current reported value: 16%. No comparable prior figure is available in the source record. to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.